Comprehensive quantitative proteomic profiling of the pharmacodynamic changes induced by MLN4924 in acute myeloid leukemia cells establishes rationale for its combination with azacitidine
Valeria Visconte(Cleveland Clinic), Jennifer S. Carew(University of Arizona), Sean A. Beausoleil(The University of Texas at San Antonio Health Science Center), Claudia M. Espitia(The University of Texas System), Mikkael A. Sekeres(University of Miami), Steffan T. Nawrocki(University of Arizona), Anthony Possemato(Cell Signaling Technology (United States)), Anjali S. Advani(Cleveland Clinic), Jaroslaw P. Maciejewski(Cleveland Clinic), Aziz Nazha, Kevin R. Kelly(Keck Hospital of USC), Yingchun Han(Cleveland Clinic), Hetty E. Carraway(Cleveland Clinic)
Cited by 26
Related Papers
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
|Annals of Oncology|2020|1.5k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
|New England Journal of Medicine|2006|1.3k
Survivin: Key Regulator of Mitosis and Apoptosis and Novel Target for Cancer Therapeutics
|Clinical Cancer Research|2008|782